



## Board Assurance Framework (BAF): April 2021


The key elements of the BAF are:

- A description of each Principal (strategic) Risk, that forms the basis of the Trust's risk framework (with corresponding corporate and operational risks defined at a Trust-wide and service level)
- Risk ratings – current (residual), tolerable and target levels
- Clear identification of primary strategic threats and opportunities that are considered likely to increase or reduce the Principal Risk, within which they are expected to materialise
- A statement of risk appetite for each threat and opportunity, to be defined by the Lead Committee on behalf of the Board (**Averse** = aim to avoid the risk entirely; **Minimal** = insistence on low risk options; **Cautious** = preference for low risk options; **Open** = prepared to accept a higher level of residual risk than usual, in pursuit of potential benefits)
- Key elements of the risk treatment strategy identified for each threat and opportunity, each assigned to an executive lead and individually rated by the lead committee for the level of assurance they can take that the strategy will be effective in treating the risk (see below for key)
- Sources of assurance incorporate the three lines of defence: (1) **Management** (those responsible for the area reported on); (2) **Risk and compliance** functions (internal but independent of the area reported on); and (3) **Independent assurance** (Internal audit and other external assurance providers)
- Clearly identified gaps in the primary control framework, with details of planned responses each assigned to a member of the Senior Leadership Team (SLT) with agreed timescales

Key to lead committee assurance ratings:

 Green = Positive assurance: the Committee is satisfied that there is reliable evidence of the appropriateness of the current risk treatment strategy in addressing the threat or opportunity  
 - no gaps in assurance or control AND current exposure risk rating = target  
 OR  
 - gaps in control and assurance are being addressed

 Amber = Inconclusive assurance: the Committee is not satisfied that there is sufficient evidence to be able to make a judgement as to the appropriateness of the current risk treatment strategy

 Red = Negative assurance: the Committee is satisfied that there is sufficient reliable evidence that the current risk treatment strategy is not appropriate to the nature and/or scale of the threat or opportunity


This approach informs the agenda and regular management information received by the relevant lead committees, to enable them to make informed judgements as to the level of assurance that they can take and which can then be provided to the Board in relation to each Principal Risk and also to identify any further action required to improve the management of those risks.

This BAF includes the following Principal Risks (PRs) to the Trust's strategic priorities:

Reference	Principal risk	Lead committee	Initial date of assessment	Last reviewed	Target risk score C x L	Previous risk score (at previous review/update) C x L	Current risk score C x L
PR1	Significant deterioration in standards of safety and care	Medical Director	01/04/2018	08/03/2021	4 x 2 = 8	4 x 5 = 20	4 x 5 = 20
PR2	Demand that overwhelms capacity	Chief Operating Officer	01/04/2018	08/03/2021	4 x 2 = 8	4 x 5 = 20	4 x 5 = 20
PR3	Critical shortage of workforce capacity and capability	Director of People	01/04/2018	27/04/2021	4 x 2 = 8	4 x 5 = 20	4 x 4 = 16
PR4	Failure to achieve the Trust's financial strategy	Chief Financial Officer	01/04/2018	27/04/2021	4 x 2 = 8	5 x 3 = 15	5 x 3 = 15
PR5	Inability to initiate and implement evidenced based improvement and innovation	Director of Culture & Improvement	17/03/2020	27/04/2021	3 x 2 = 6	3 x 3 = 9	3 x 3 = 9
PR6	Working more closely with local health and care partners does not fully deliver the required benefits	Chief Executive Officer	01/04/2020	13/04/2021	2 x 2 = 4	2 x 3 = 6	2 x 3 = 6
PR7	Major disruptive incident	Director of Corporate Affairs	01/04/2018	13/04/2021	4 x 1 = 4	4 x 3 = 12	4 x 2 = 8

## Board Assurance Framework (BAF): April 2021

<b>Principal risk</b> <small>(what could prevent us achieving this strategic priority)</small>	<b>PR 1: Significant deterioration in standards of safety and care</b> Significant deterioration in standards of safety and quality of patient care across the Trust resulting in substantial incidents of avoidable harm and poor clinical outcomes						<b>Strategic priority</b>	1. To provide outstanding care
<b>Lead Committee</b>	Quality	<b>Risk rating</b>	<b>Current exposure</b>	<b>Tolerable</b>	<b>Target</b>	<b>Risk type</b>	Patient harm	
<b>Executive lead</b>	Medical Director	<b>Consequence</b>	<b>4. High</b>	4. High	4. High	<b>Risk appetite</b>	Minimal	
<b>Initial date of assessment</b>	01/04/2018	<b>Likelihood</b>	<b>5. Very likely</b>	3. Possible	2. Unlikely			
<b>Last reviewed</b>	08/03/2021	<b>Risk rating</b>	<b>20. Significant</b>	<b>12. High</b>	<b>8. Medium</b>			
<b>Last changed</b>	08/03/2021							



<b>Strategic threat</b> <small>(what might cause this to happen)</small>	<b>Primary risk controls</b> <small>(what controls/ systems &amp; processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)</small>	<b>Gaps in control</b> <small>(Specific areas / issues where further work is required to manage the risk to accepted appetite/tolerance level)</small>	<b>Plans to improve control</b> <small>(are further controls possible in order to reduce risk exposure within tolerable range?)</small>	<b>Sources of assurance (and date)</b> <small>(Evidence that the controls/ systems which we are placing reliance on are effective)</small>	<b>Gaps in assurance / actions to address gaps and issues relating to COVID-19</b> <small>(Insufficient evidence as to effectiveness of the controls or negative assurance)</small>	<b>Assurance rating</b>
A widespread loss of organisational focus on patient safety and quality of care leading to increased incidence of avoidable harm, exposure to 'Never Events', higher than expected mortality, and significant reduction in patient satisfaction	<ul style="list-style-type: none"> <li>Clinical service structures, accountability &amp; quality governance arrangements at Trust, division &amp; service levels including: <ul style="list-style-type: none"> <li>Monthly meeting of Quality &amp; Assurance Safety Cabinet (QASC) with work programme aligned to CQC registration regulations</li> <li>Advancing Quality Programme and AQP oversight group</li> <li>Nursing and Midwifery and AHP Business meeting</li> </ul> </li> <li>Clinical policies, procedures, guidelines, pathways, supporting documentation &amp; IT systems</li> <li>Clinical audit programme &amp; monitoring arrangements</li> <li>Clinical staff recruitment, induction, mandatory training, registration &amp; re-validation</li> <li>Defined safe medical &amp; nurse staffing levels for all wards &amp; departments (Nursing safeguards monitored by Chief Nurse)</li> <li>Ward assurance/ metrics and accreditation programme</li> <li>Nursing &amp; Midwifery Strategy</li> <li>AHP Strategy</li> <li>Scoping and sign-off process for incidents and Sis</li> </ul>	Intranet currently contains some out of date clinical information that may still be accessible	Intranet documents review <b>SLT Lead:</b> Head of Communications <b>Timescale:</b> end March 2021	<b>Management:</b> Learning from deaths Report to QC and Board; Quarterly Strategic Priority Report to Board; Divisional risk reports to Risk Committee bi-annually; Guardian of Safe Working report to Board qrtly  <u>Quality and Governance Reporting Pathway; Quality Assurance and Safety Cabinet → Quality Committee Reports include:</u> <ul style="list-style-type: none"> <li>DPR Report to QASC monthly and QC bi-monthly</li> <li>QASC assurance report to QC bi-monthly</li> <li>Patient Safety Culture (PSC) programme</li> <li>EoLC Annual Report to QC</li> <li>Safeguarding Annual Report to QC</li> <li>CYPP report to QC quarterly</li> <li>Medical Education update report to QC Jul '19</li> <li>Medicines Optimisation Annual Report to QC</li> <li>Senior Leadership Walkarounds weekly</li> </ul> <u>Outputs from internal reviews against External National Reports including:</u> <ul style="list-style-type: none"> <li>HSIB Thromboembolic Maternity Report (Oct 2020)</li> <li>National Audit for Care of end of Life (Sep 2020)</li> <li>Ockenden Report (Dec 2020)</li> </ul>	None	Positive
				<b>Risk &amp; compliance:</b> Quality Dashboard and SOF to QASC Monthly; Quality Account Report Qtrly to QASC and QC; SI & Duty of Candour report to QASC monthly; CQC report to QC bi-monthly; Significant Risk Report to RC monthly  <b>Independent assurance:</b> CQC Inspection Report 2020 CQC Insight tool to QPSC monthly; CQC Rating and oversight; IA (360) Transfer of Handover assurance report QC Sep '18; Antenatal & newborn screening peer review QC Nov '18; Sherwood Birthing Unit Audit to PSQG 2018; ICNARC Quarterly Report; SHOT report to QPSC 2018; EoLC Audit 2018; PHQA visit for Smoke-free Life; Audit Inpatient Survey 2017; Maternity Inpatient Survey 2018; CQC Insight		

Formatted: Font: Not Bold, Underline  
Formatted: Font: Not Bold, Underline  
Formatted: Font: Not Bold  
Formatted: Font: Not Bold  
Formatted: Font: Not Bold

Formatted: List Paragraph, Indent: Left: 0.19 cm, Hanging: 0.5 cm, Bulleted + Level: 1 + Aligned at: 0.63 cm + Indent at: 1.27 cm  
Formatted: Font: (Default) Calibri, 10 pt, Font color: Black  
Formatted: Font: (Default) Calibri, 10 pt, Underline, Font color: Black

## Board Assurance Framework (BAF): April 2021

Strategic threat <small>(what might cause this to happen)</small>	Primary risk controls <small>(what controls/ systems &amp; processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)</small>	Gaps in control <small>(Specific areas / issues where further work is required to manage the risk to accepted appetite/tolerance level)</small>	Plans to improve control <small>(are further controls possible in order to reduce risk exposure within tolerable range?)</small>	Sources of assurance (and date) <small>(Evidence that the controls/ systems which we are placing reliance on are effective)</small>	Gaps in assurance / actions to address gaps and issues relating to COVID-19 <small>(Insufficient evidence as to effectiveness of the controls or negative assurance)</small>	Assurance rating
				<p><del>Tool to QPSC monthly and QC bi-monthly; GMC Feedback 2018; NNAP Audit 2018; Care Quality Commission / External Regulation Report to QC Mar '19; Medicines Optimisation Report to QC Mar '19; Care Quality Commission / External Regulation Report to QC Mar '19; Medicines Optimisation Report to QC Mar '19</del></p> <p><u>Screening Quality Assurance Services assessments and reports of:</u></p> <ul style="list-style-type: none"> <li>- <u>Antenatal and New-born screening</u></li> <li>- <u>Breast Cancer Screening Services</u></li> <li>- <u>Bowel Cancer Screening Services</u></li> <li>- <u>Cervical Screening Services</u></li> </ul> <p><u>External Accreditation/Regulation annual assessments and reports of:</u></p> <ul style="list-style-type: none"> <li>- <u>Pathology (UKAS)</u></li> <li>- <u>Endoscopy Services (JAG)</u></li> <li>- <u>Medical Equipment and Medical Devices (BSI)</u></li> <li>- <u>Blood Transfusion Annual Compliance Report (MHRA)</u></li> </ul>		
<p>An <b>outbreak of infectious disease</b> (such as pandemic influenza; Coronavirus; norovirus; infections resistant to antibiotics) that forces closure of one or more areas of the hospital</p>	<ul style="list-style-type: none"> <li>▪ Infection prevention &amp; control (IPC) programme Policies/ Procedures; Staff training; Environmental cleaning audits</li> <li>▪ PFI arrangements for cleaning services</li> <li>▪ Root Cause Analysis and Root Cause Analysis Group</li> <li>▪ Reports from Public Health England received and acted upon</li> <li>▪ Infection control annual plan developed in line with the Hygiene Code</li> <li>▪ Influenza and Covid vaccination programmes</li> <li>▪ Public communications re: norovirus and infectious diseases</li> <li>▪ Coronavirus identification and management process</li> </ul>	None	N/A	<p><b>Management:</b> Divisional reports to IPC Committee (every 6 weeks); IPC Annual Report to QC and Board; Water Safety Group; <a href="#">IPC BAF report to QASC and QC</a></p> <p><b>Risk &amp; compliance:</b> IPC Committee report to QPSC qtrly; SOF Performance Report to Board monthly; IPC Clinical audits in IPCC report to QPSC qtrly</p> <p><b>Independent assurance:</b> Internal audit plan; CQC Rating Good with Outstanding for Care <del>Aug '18</del> <u>May '20</u>; PLACE Assessment and Scores Estates Governance bi-monthly; Public Health England attendance at IPC Committee; Influenza vaccination cumulative number of staff vaccinated; HSE visit Dec '20 – no concerns highlighted <a href="#">IPC BAF Peer Review by Medway Trust</a> <a href="#">HSE External assessment and report</a> <a href="#">HSIB IPC assessment and report</a></p>	<p>Learning from the impact on activity, patient safety and staffing due to COVID-19 wave 1</p> <p>Constraints of critical care capacity and PPE availability dependent on the size of future waves and restoration activity</p> <p>Business case to enhance oxygen capacity/flow has been delivered – awaiting further instruction from NHSE/I</p>	Inconclusive

Formatted: Underline

Formatted: Underline

Formatted: Underline

Formatted: Underline

Formatted: Underline

Formatted: List Paragraph, Indent: Left: 0.19 cm, Hanging: 0.5 cm, Bulleted + Level: 1 + Aligned at: 0.63 cm + Indent at: 1.27 cm

Formatted: Underline

Formatted: Underline

Formatted: Underline

Formatted: Underline

Formatted: Underline


Formatted: List Paragraph, Indent: Left: 0.19 cm, Hanging: 0.5 cm, Bulleted + Level: 1 + Aligned at: 0.63 cm + Indent at: 1.27 cm

Formatted: Font: Not Bold

Formatted: Font: (Default) Calibri, 10 pt, Font color: Black

## Board Assurance Framework (BAF): April 2021


<b>Principal risk</b> <small>(what could prevent us achieving this strategic priority)</small>	<b>PR 2: Demand that overwhelms capacity</b> Demand for services that overwhelms capacity resulting in a deterioration in the quality, safety and effectiveness of patient care						<b>Strategic priority</b>	1. To provide outstanding care
<b>Lead Committee</b>	Quality	<b>Risk rating</b>	<b>Current exposure</b>	<b>Tolerable</b>	<b>Target</b>	<b>Risk type</b>	Patient harm	
<b>Executive lead</b>	Chief Operating Officer	<b>Consequence</b>	<b>4. High</b>	4. High	4. High	<b>Risk appetite</b>	Minimal	
<b>Initial date of assessment</b>	01/04/2018	<b>Likelihood</b>	<b>5. Very likely</b>	4. Somewhat likely	2. Unlikely			
<b>Last reviewed</b>	08/03/2021	<b>Risk rating</b>	<b>20. Significant</b>	<b>16. Significant</b>	<b>8. Medium</b>			
<b>Last changed</b>	08/03/2021							



<b>Strategic threat</b> <small>(what might cause this to happen)</small>	<b>Primary risk controls</b> <small>(what controls/ systems &amp; processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)</small>	<b>Gaps in control</b> <small>(Specific areas / issues where further work is required to manage the risk to accepted appetite/ tolerance level)</small>	<b>Plans to improve control</b> <small>(are further controls possible in order to reduce risk exposure within tolerable range?)</small>	<b>Sources of assurance (and date)</b> <small>(Evidence that the controls/ systems which we are placing reliance on are effective)</small>	<b>Gaps in assurance / actions to address gap and issues relating to COVID-19</b> <small>(Insufficient evidence as to effectiveness of the controls or negative assurance)</small>	<b>Assurance rating</b>
<b>Threat: Growth in demand for care</b> caused by an ageing population (forecast annual increase in emergency demand of 4-5% per annum); reduced social care funding and increased acuity leading to more admissions and longer length of stay, or a reduction in capacity to meet current and future demand due to the impact of COVID-19	<ul style="list-style-type: none"> <li>Emergency admission avoidance schemes across the system</li> <li>Single streaming process for ED &amp; Primary Care – regular meetings with NEMs</li> <li>Trust and System escalation process</li> <li>Cancer Improvement plan</li> <li>Trust leadership of and attendance at A&amp;E Board</li> <li>Patient pathway, some of which are joint with NUH</li> <li>Inter-professional standards across the Trust to ensure turnaround times such as diagnostics are completed within 1 day</li> <li>Proactive system leadership engagement from SFH into Better Together Alliance Delivery Board</li> <li>Patient Flow Programme</li> <li>SFH internal Winter capacity plan &amp; Mid Notts system capacity plan</li> <li>Referral management systems shared between primary and secondary care</li> <li>MSK pathways</li> <li>COVID-19 Incident planning and governance process</li> <li>Some cancer services maintained during COVID-19</li> <li>Risk assessments to prioritise individual patients</li> <li><b>Recovery Committee</b></li> </ul>	Robust delivery of the demand management schemes across the system	On-going discussions across ICS and specifically with NUH to describe future service delivery. Continued development of ICS clinical service strategy, Tomorrow's NUH Refresh NUH/SFH Exec to Exec forum 6-monthly progress updates to Board <b>SLT Lead:</b> Medical Director <b>Timescale:</b> end March 2021	<b>Management:</b> Performance management reporting arrangements between Divisions, Service Lines and Executive Team; Winter Plan to Board Oct '20; Exec to Exec meetings; Cancer 62 day improvement plan to Board; Planning documents for 19/20 to identify clear demand and capacity gaps/bridges; Identifying and capturing Potential Harm Resultant from COVID-19 Pandemic report to Board Jun '20; COVID-19 Recovery Plan to Board Sep '20; Elective Services Report to Recovery Committee monthly <b>Risk &amp; compliance:</b> Divisional risk reports to Risk Committee bi-annually; Significant Risk Report to RC monthly; Single Oversight Framework Integrated Monthly Performance Report to Board; Incident Control Team governance structure to TMT Mar '20 <b>Independent assurance:</b> <del>IA review of outpatient Demand and capacity modelling Jul '18;</del> <del>Regulatory Framework – Performance Standards (Emergency Readmissions Indicator) Follow Up Sep '18;</del> NHSI Intensive Support Team review of cancer processes May '20		Positive
<b>Threat &amp; Opportunity: Operational failure of General Practice</b> to cope with demand resulting in even higher demand for secondary care as the 'provider of last resort'	<ul style="list-style-type: none"> <li>Visibility on the CCG risk register/BAF entry relating to operational failure of General Practice</li> <li>Engagement in Integrated Care System (ICS), and assuming a leading role in Integrated Care Provider development</li> <li>Weekly Executive meeting with the CCGs</li> <li>Weekly Mid Notts Network Calls</li> </ul>			<b>Management:</b> Routine mechanism for sharing of CCG and SFH risk registers – particularly with regard to risks for primary care staffing and demand <b>Independent assurance:</b> 'Drivers of demand' discussed at Board Aug '19	Lack of recent GP vacancy rates data received from Primary Care  Pursue current GP vacancy data <b>SLT Lead:</b> COO <b>Timescale:</b> end <del>January 2021</del> <b>March '21</b>	Inconclusive
<b>Threat &amp; Opportunity:</b> Drop in operational performance of neighbouring providers that creates a shift in the flow of patients and referrals to SFH	<ul style="list-style-type: none"> <li>Engagement in Integrated Care System (ICS), and assuming a leading role in Integrated Care Provider development</li> <li>Horizon scanning with neighbour organisations via meetings between relevant Executive Directors</li> <li>Weekly management meeting with the Service Director from Notts HC</li> <li>Bilateral work – Strategic Partnership forum</li> </ul>	None	N/A	<b>Risk and compliance:</b> Divisional NUH/SFH strategic partnership forum minutes and action log; NUH service support to SFH paper to Executive Team	Lack of control over the flow of patients from the surrounding area	Inconclusive

## Board Assurance Framework (BAF): April 2021

<b>Principal risk</b> <small>(what could prevent us achieving this strategic priority)</small>	<b>PR 3: Critical shortage of workforce capacity and capability</b> A shortage of workforce capacity and capability resulting in a deterioration of staff experience, morale and well-being which can have an adverse impact on patient care						<b>Strategic priority</b>	3: To maximise the potential of our workforce
<b>Lead Committee</b>	People, Culture & Improvement	<b>Risk rating</b>	<b>Current exposure</b>	<b>Tolerable</b>	<b>Target</b>	<b>Risk type</b>	Services	
<b>Executive lead</b>	Executive Director of People	<b>Consequence</b>	<b>4. High</b>	4. High	4. High	<b>Risk appetite</b>	Cautious	
<b>Initial date of assessment</b>	01/04/2018	<b>Likelihood</b>	<del>5. Very likely</del> 4. Somewhat likely	4. Somewhat likely	2. Unlikely			
<b>Last reviewed</b>	27/04/2021	<b>Risk rating</b>	<del>20-16. Significant</del>	16. Significant	<b>8. Medium</b>			
<b>Last changed</b>	27/04/2021							



Formatted Table

<b>Strategic threat</b> <small>(what might cause this to happen)</small>	<b>Primary risk controls</b> <small>(what controls/ systems &amp; processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)</small>	<b>Gaps in control</b> <small>(Specific areas / issues where further work is required to manage the risk to accepted appetite/ tolerance level)</small>	<b>Plans to improve control</b> <small>(are further controls possible in order to reduce risk exposure within tolerable range?)</small>	<b>Sources of assurance (and date)</b> <small>(Evidence that the controls/ systems which we are placing reliance on are effective)</small>	<b>Gaps in assurance / actions to address gaps and issues relating to COVID-19</b>	<b>Assurance rating</b>
<b>Threat: Inability to attract and retain staff</b> due to demographic changes (including a significant impact of external factors and/or unforeseen circumstances) and shifting cultural attitudes to careers, combined with employment market factors (such as reduced availability and increased competition) resulting in critical workforce gaps in some clinical services	<ul style="list-style-type: none"> <li>People Culture and Improvement Strategy</li> <li>People and Inclusion Cabinet</li> <li>Culture and Improvement Cabinet</li> <li>Medical and Nursing task force</li> <li>Activity, Workforce and Financial plan</li> <li>2 year workforce plan supported by Workforce Planning Group and review processes (consultant job planning; workforce modelling; winter capacity plans)</li> <li>Vacancy management and recruitment systems and processes</li> <li>TRAC system for recruitment; e-Rostering systems and procedures used to plan staff utilisation</li> <li>Defined safe medical &amp; nurse staffing levels for all wards and departments / Safe Staffing Standard Operating Procedure</li> <li>Temporary staffing approval and recruitment processes with defined authorisation levels</li> <li>Education partnerships</li> <li>Director of People attendance at People and Culture Board</li> <li>Workforce planning for system work stream</li> <li>Communications issued regarding HMRC taxation rules on pensions and provision of pensions advice</li> <li>Pensions restructuring payment introduced</li> <li>Risk assessments for at-risk staff groups</li> </ul>	<p>Lack of Divisional ownership and understanding of their workforce issues</p> <p><del>Insufficient staff to meet the Phase 3 Activity Plan</del></p>	<p>Implementation of the People, Culture and Improvement Strategy (People and Inclusion)</p> <p><b>SLT Lead:</b> Executive Director of People</p> <p><b>Timescale:</b> <del>April 2021 complete</del> – submitted to P,C&amp;I Committee for approval</p> <p><u>Deliver the People, Culture and Improvement Strategy (People and Inclusion)</u></p> <p><b>SLT Lead:</b> Executive Director of People</p> <p><b>Timescale:</b> <del>March 2022</del></p> <p>Increase staffing to meet the Phase 3 Activity Plan</p> <p><b>SLT Lead:</b> Executive Director of People</p> <p><b>Timescale:</b> <del>March 2021 complete</del></p>	<p><b>Management:</b> Nursing &amp; Midwifery Strategy 2018/20; Quarterly Strategic Priority Report to Board; AHP Strategy to Board Sep '19; Nursing and Midwifery and AHP six monthly staffing report – Nov 20; Workforce and OD ICS/ICP update quarterly; Quarterly Assurance reports on People &amp; Inclusion and Culture &amp; Improvement to People Culture and Improvement Committee; People Culture and Improvement: COVID-19 Update May '20; Recruitment &amp; Retention report monthly</p> <p><b>Risk and compliance:</b> Risk Committee significant risk report Monthly; HR &amp; Workforce planning report Risk Committee; SOF – Workforce Indicators (Monthly); Bank and agency report (monthly); Guardian of safe working report to Board Nov '20</p> <p><b>Independent assurance:</b> Well-led report CQC; NHSI use of resources report; IA Recruitment &amp; Retention report Jan '19 – Significant Assurance; EU Exit Risk System Overview – Nottingham and Nottinghamshire System Dec '20; <u>Pre-employment Checks internal audit report Feb '21 – significant assurance; HSJ Award for Acute Trust of the Year 2021</u></p>	<p>Staff becoming infected, leading to increased sickness absence</p> <p>Staff working in unfamiliar roles</p> <p>Staff mental health as a result of psychological trauma</p>	Inconclusive

Formatted: Font: Not Bold


Formatted: Not Highlight

## Board Assurance Framework (BAF): April 2021

Strategic threat <i>(what might cause this to happen)</i>	Primary risk controls <i>(what controls/ systems &amp; processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)</i>	Gaps in control <i>(Specific areas / issues where further work is required to manage the risk to accepted appetite/ tolerance level)</i>	Plans to improve control <i>(are further controls possible in order to reduce risk exposure within tolerable range?)</i>	Sources of assurance (and date) <i>(Evidence that the controls/ systems which we are placing reliance on are effective)</i>	Gaps in assurance / actions to address gaps and issues relating to COVID-19	Assurance rating
<p><b>Threat:</b> A significant loss of workforce productivity arising from a short-term reduction in staff availability or a reduction in effort above and beyond contractual requirements amongst a substantial proportion of the workforce and/or loss of experienced colleagues from the service, or caused by other factors such as poor job satisfaction, lack of opportunities for personal development, on-going pay restraint, workforce fatigue or wellbeing issues, or failure to achieve consistent values and behaviours in line with desired culture This could also lead to lack of engagement with patients, resulting in failure to address patient empowerment and self-help and failure to work across the system to empower patients and carers to enable personalised patient centred care</p>	<ul style="list-style-type: none"> <li>▪ People Culture and Improvement Strategy</li> <li>▪ People and Inclusion Cabinet</li> <li>▪ Culture and Improvement Cabinet</li> <li>▪ Chief Executive's blog / Staff Communication bulletin</li> <li>▪ Engagement events with Staff Networks (BAME, LGBT, WAND, Time to Change)</li> <li>▪ Schwartz rounds</li> <li>▪ Learning from COVID</li> <li>▪ Staff morale identified as 'profile risk' in Divisional risk registers</li> <li>▪ Star of the month/ milestone events</li> <li>▪ Divisional action plans from staff survey</li> <li>▪ Policies (inc. staff development; appraisal process; sickness and relationships at work policy)</li> <li>▪ Just and restorative culture</li> <li>▪ Influenza vaccination programme</li> <li>▪ COVID-19 vaccination programme</li> <li>▪ Staff wellbeing drop-in sessions</li> <li>▪ Staff counselling / Occ Health support</li> <li>▪ Enhanced equality, diversity and inclusion focus on workforce demographics</li> <li>▪ Freedom to Speak Up Guardian and champion networks</li> <li>▪ Emergency Planning, Resilience &amp; Response (EPRR) arrangements for temporary loss of essential staffing (including industrial action and extreme weather event)</li> </ul>	<p>Inequalities in staff wellbeing across protected characteristics groups</p>	<p>Implementation of the People, Culture and Improvement Strategy (Culture and Improvement) <b>SLT Lead:</b> Executive Director of People <b>Timescale:</b> <a href="#">April 2021 complete – submitted to P,C&amp;I Committee for approval</a></p> <p><a href="#">Deliver the People, Culture and Improvement Strategy (Culture and Improvement)</a> <b>SLT Lead:</b> Executive Director of People <b>Timescale:</b> <a href="#">March 2022</a></p> <p>Completion and delivery of WRES and WDES action plans <b>SLT Lead:</b> Executive Director of People <b>Timescale:</b> <a href="#">March 2021 complete</a></p> <p>Review and refine the current health and wellbeing offer <b>SLT Lead:</b> Executive Director of People <b>Timescale:</b> <a href="#">April 2021 complete</a></p> <p><a href="#">Deliver the Equality, Diversity and Inclusivity Strategy</a> <b>SLT Lead:</b> Executive Director of People <b>Timescale:</b> <a href="#">March 2022</a></p>	<p><b>Management:</b> Staff survey, action plan and annual report to Board Oct '20; Diversity &amp; Inclusion Annual report Jun '20; WRES and WDES report to Board Jun '20; Combined assurance report addressing; D&amp;I, Violence &amp; Aggression, Restraints Oct 20 Board; Quarterly Assurance reports on People &amp; Inclusion and Culture &amp; Improvement to People Culture and Improvement Committee; People Culture and Improvement: COVID-19 Update May '20; Equality &amp; Diversity presentation to Board Aug '20; Business Continuity exercises – post exercise reports through Resilience Assurance Committee (rolling program) <b>Risk and compliance:</b> EPRR Report (bi-annually); Freedom to speak up self-review Board Oct '20; Freedom to Speak Up Guardian report to Board Dec '20; Gender Pay Gap report to Board Mar '20; TRAC Performance Report to P, OD&amp;C quarterly; Interim NHS People Plan self-assessment to People Culture &amp; Inclusion Sep '20; Significant Risk Report to RC monthly; <a href="#">Gender Pay Gap report to Board Apr '21</a> <b>Independent assurance:</b> National Staff Survey <a href="#">Nov '19 Mar '21</a>; SFFT/Pulse surveys (Quarterly); Well-led report CQC; <a href="#">Confirm and Challenge by NHS England Regional team and CCGs Sep '18</a>; <a href="#">Internal Audit Business Continuity and Emergency Planning Sep '18</a></p>	<p>Reduction in available staff due to COVID-19, e.g. shielding of vulnerable staff groups and social distancing; redeployment to the vaccination programme</p> <p>Reduction in effort above and beyond contractual requirements due to COVID-19 service restrictions</p> <p>Reluctance of some staff members to return to work due to COVID-19-associated health concerns</p> <p>Restrictions to deployment of key staff due to reduced availability of Mandatory and Statutory Training, and the consequential expiry of certification</p>	<p>Inconclusive</p>

## Board Assurance Framework (BAF): April 2021

<b>Principal risk</b> <small>(what could prevent us achieving this strategic priority)</small>	<b>PR 4: Failure to achieve the Trust's financial strategy</b> Failure to achieve agreed trajectories resulting in regulatory action						<b>Strategic priority</b>	5: To achieve better value
<b>Lead Committee</b>	Finance	<b>Risk rating</b>	<b>Current exposure</b>	<b>Tolerable</b>	<b>Target</b>	<b>Risk type</b>	Regulatory action	
<b>Executive lead</b>	Chief Financial Officer	<b>Consequence</b>	<b>5. Very high</b>	4. High	4. High	<b>Risk appetite</b>	Cautious	
<b>Initial date of assessment</b>	01/04/2018	<b>Likelihood</b>	<b>3. Possible</b>	3. Possible	2. Unlikely			
<b>Last reviewed</b>	27/04/2021	<b>Risk rating</b>	<b>15. Significant</b>	<b>12. High</b>	<b>8. Medium</b>			
<b>Last changed</b>	27/04/2021							



<b>Strategic threat</b> <small>(what might cause this to happen)</small>	<b>Primary risk controls</b> <small>(what controls/ systems &amp; processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)</small>	<b>Gaps in control</b> <small>(are further controls possible in order to reduce risk exposure within tolerable range?)</small>	<b>Plans to improve control</b>	<b>Sources of assurance (and date)</b> <small>(Evidence that the controls/ systems which we are placing reliance on are effective)</small>	<b>Gaps in assurance / actions to address gaps</b>	<b>Assurance rating</b>
<b>Threat:</b> A reduction in funding or change in financial trajectory or unexpected event resulting in an increased Financial Improvement Plan (FIP) requirement to reduce the scale of the financial deficit, without having an adverse impact on quality and safety	<ul style="list-style-type: none"> <li>5 year long term financial model</li> <li>Working capital support through agreed loan arrangements</li> <li>Annual plan, including control total consideration; reduction of underlying financial deficit and unwinding of the PFI benefit by £0.5m annually</li> <li>Engagement with the Better Together alliance programme</li> <li><u>Transformation and Efficiency Cabinet FIP Board</u>, FIP planning processes and PMO coordination of delivery</li> <li>Delivery of budget holder training workshops and enhancements to financial reporting</li> <li>A full 'wash up' of portfolio planning, delivery and engagement conducted; recovery plan in place, Board approved &amp; governance in place</li> <li>Medical Pay Task Force action plan in place</li> <li>Close working with ICS partners to identify system-wide <u>planning, transformation and</u> cost reductions</li> <li>Executive oversight of commitments</li> <li>All costs and required cash associated with COVID-19 funded in full for period 1/4/20 to 30/9/20</li> <li><u>2021/22 Planning guidance confirms continuation of 20/21 funding regime for H1</u></li> </ul>	<p>No long term commitment received for liquidity / cash support</p> <p>Lack of identification of opportunities for recurrent delivery of FIP</p> <p>Lack of clarity on the financial regime for 21/22 <u>H2</u></p> <p><u>£9m deficit forecast in M7-12 resource envelope</u></p>	<p>Full receipt of required cash (FRF) following delivery of NHSI required future trajectories <b>SLT Lead:</b> Chief Financial Officer <b>Timescale:</b> 2021/22 <u>H2</u> plan submission date (TBC by NHSI)</p> <p>Full review of ability to improve recurrent delivery of FIP within financial planning for 2021/22 <b>SLT Lead:</b> Director of Culture and Improvement <b>Timescale:</b> 2021/22 <u>H2</u> plan submission date (TBC by NHSI)</p> <p><u>H1 and H2</u> budget setting process for 2021/22 to include enhanced confirm and challenge <b>SLT Lead:</b> Chief Financial Officer <b>Timescale:</b> 2021/22 H2 plan submission date (TBC by NHSI)</p> <p>Monthly reviews of forecasts by CFO, monitoring and reporting of delivery of forecast (not plan), no re-investment of favourable variance to forecast, adverse variances to be recovered <b>SLT Lead:</b> Chief Financial Officer <b>Timescale:</b> October 2020 to March 2021 <u>- complete</u></p> <p>Weekly review meetings with NHSI to explain the 2019/20 impact on current £9m deficit <b>SLT Lead:</b> Chief Financial Officer <b>Timescale:</b> October 2020 to March 2021 <u>- complete</u></p>	<p><b>Management:</b> <u>Delivery of improved 20/21 financial position</u>; CFO's Financial Reports &amp; FIP Summary (Monthly); Quarterly Strategic Priority Report to Board; Alliance Progress Report &amp; STP FIP (at each Finance Committee meeting); Investment governance work programme; Divisional risk reports to Risk Committee bi-annually</p> <p><b>Risk and compliance:</b> Risk Committee significant risk report Monthly;</p> <p><b>Independent assurance:</b> Internal Audit Report FIP/ QIPP (Jul '18); EY Financial Recovery Plan; all costs associated with COVID-19 reimbursed in full to 30/9/20</p>	<p><u>Awaiting H2 2021/22 NHSI/E planning guidance</u></p>	Inconclusive
<b>Threat:</b> ICS system deficit results in a negative financial impact to the Trust	<ul style="list-style-type: none"> <li>Full participation in ICS planning</li> <li>SFH plan consistency with ICS plan</li> <li><u>ICS DoFs Group</u></li> <li><u>ICS Strategy and Delivery Group</u></li> <li><u>ICS Planning Group</u></li> <li><u>ICS Financial Sustainability Group</u></li> </ul>	ICS underlying financial deficit	<p>Full participation in the development of the ICS Financial Strategy and aligned payment mechanisms <b>SLT Lead:</b> Chief Financial Officer <b>Timescale:</b> <u>31/3/2021</u> 2021/22 H2 plan submission date (TBC by NHSI)</p>	<p><b>Risk and compliance:</b> ICS financial reports to Finance Committee; ICS Board updates to SFH Trust Board</p>	<p><u>Awaiting H2 2021/22 NHSI/E planning guidance</u></p>	Inconclusive

Formatted: Font: Not Bold

Formatted: Not Highlight

## Board Assurance Framework (BAF): April 2021

<b>Principal risk</b> <small>(what could prevent us achieving this strategic priority)</small>	<b>PR 5: Inability to initiate and implement evidence-based improvement and innovation</b> Lack of support, capability and agility to optimise strategic and operational opportunities to improve patient care						<b>Strategic priority</b>	4: To continuously learn and improve
<b>Lead Committee</b>	People, Culture & Improvement	<b>Risk rating</b>	<b>Current exposure</b>	<b>Tolerable</b>	<b>Target</b>	<b>Risk type</b>	Patient Harm	
<b>Executive lead</b>	Director of Culture & Improvement	<b>Consequence</b>	<b>3. Moderate</b>	3. Moderate	3. Moderate	<b>Risk appetite</b>	Cautious	
<b>Initial date of assessment</b>	17/03/2020	<b>Likelihood</b>	<b>3. Possible</b>	3. Possible	2. Unlikely			
<b>Last reviewed</b>	27/04/2021	<b>Risk rating</b>	<b>9. Medium</b>	<b>9. Medium</b>	<b>6. Low</b>			
<b>Last changed</b>	27/04/2021							

Legend:  
— Current risk level  
- - - Tolerable risk level  
. . . Target risk level

<b>Strategic threat</b> <small>(what might cause this to happen)</small>	<b>Primary risk controls</b> <small>(what controls/ systems &amp; processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)</small>	<b>Gaps in control</b> <small>(are further controls possible in order to reduce risk exposure within tolerable range?)</small>	<b>Plans to improve control</b> <small>(are further controls possible in order to reduce risk exposure within tolerable range?)</small>	<b>Sources of assurance (and date)</b> <small>(Evidence that the controls/ systems which we are placing reliance on are effective)</small>	<b>Gaps in assurance / actions to address gaps and issues relating to COVID-19</b>	<b>Assurance rating</b>
<b>Threat:</b> Lack of understanding and agility resulting in reduced efficiency and effectiveness around how we provide care for patients	<ul style="list-style-type: none"> <li>▪ Digital Strategy</li> <li>▪ Improvement Strategy</li> <li>▪ People, Culture &amp; Improvement Committee</li> <li>▪ Leadership development programmes</li> <li>▪ Talent management map</li> <li>▪ Programme Management Office</li> <li>▪ Culture &amp; Improvement Cabinet</li> <li>▪ Transformation Cabinet</li> <li>▪ <u>Ideas generator platform</u></li> </ul>		<p>Establish an ideas generator platform  <b>SLT Lead:</b> Director of Culture and Improvement  <b>Timescale:</b> <u>end March 2021 complete</u></p> <p><u>Introduction of a newly designed QI training offer</u>  <b>SLT Lead:</b> Director of Culture and Improvement  <b>Timescale:</b> <u>May 2021</u></p> <p><u>Proposal for Continuous Improvement in SFH</u>  <b>SLT Lead:</b> Director of Culture and Improvement  <b>Timescale:</b> <u>May 2021</u></p> <p><u>Establishment of an Innovation Hub</u>  <b>SLT Lead:</b> Director of Culture and Improvement  <b>Timescale:</b> <u>June 2021</u></p> <p><u>Recruit a Chief Information Officer</u>  <b>SLT Lead:</b> Medical Director  <b>Timescale:</b> <u>August 2021</u></p>	<p><b>Management:</b> Monthly <u>FIP/Transformation and Efficiency</u> report to FC; Clinical Audit &amp; Improvement report to QASC quarterly; Culture &amp; Improvement Assurance Report to PC&amp;IC bi-monthly</p> <p><b>Risk and compliance:</b> SOF Culture and Improvement indicators; <u>SFH breakthrough objectives to Board quarterly</u></p> <p><b>Independent assurance:</b> none currently in place</p>	Delays in <u>training</u> , planned improvement and innovation programmes due to COVID-19	Positive

Formatted: Font: Not Bold

Formatted: Font: 10 pt



## Board Assurance Framework (BAF): April 2021


<b>Principal risk</b> <small>(what could prevent us achieving this strategic priority)</small>	<b>PR 6: Working more closely with local health and care partners does not fully deliver the required benefits</b> Influencing the wider determinants of health and improving our collective financial position requires close partnership working. This may be difficult because of differences in governance, objectives and appetite for and ability to change.						<b>Strategic priority</b>	2: To promote and support health and wellbeing
<b>Lead Committee</b>	Risk	<b>Risk rating</b>	<b>Current exposure</b>	<b>Tolerable</b>	<b>Target</b>	<b>Risk type</b>	Services	
<b>Executive lead</b>	Chief Executive Officer	<b>Consequence</b>	<b>2. Low</b>	2. Low	2. Low	<b>Risk appetite</b>	Cautious	
<b>Initial date of assessment</b>	01/04/2020	<b>Likelihood</b>	<b>3. Possible</b>	4. Possible	2. Unlikely			
<b>Last reviewed</b>	13/04/2021	<b>Risk rating</b>	<b>6. Low</b>	<b>8. Medium</b>	<b>4. Low</b>			
<b>Last changed</b>	09/03/2021							

<b>Strategic threat</b> <small>(what might cause this to happen)</small>	<b>Primary risk controls</b> <small>(what controls/ systems &amp; processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)</small>	<b>Gaps in control</b> <small>(are further controls possible in order to reduce risk exposure within tolerable range?)</small>	<b>Plans to improve control</b> <small>(are further controls possible in order to reduce risk exposure within tolerable range?)</small>	<b>Sources of assurance (and date)</b> <small>(Evidence that the controls/ systems which we are placing reliance on are effective)</small>	<b>Gaps in assurance / actions to address gaps and issues relating to COVID-19</b>	<b>Assurance rating</b>
<p><b>Threat:</b> Conflicting priorities, financial pressures (system financial plan misalignment) and/or ineffective governance resulting in a breakdown of relationships amongst ICS and ICP partners and an inability to influence further integration of services across acute, mental, primary and social care</p>	<ul style="list-style-type: none"> <li>Mid-Nottinghamshire Integrated Care Partnership Board</li> <li>Mid-Nottinghamshire ICP Executive formed May 2020</li> <li>Mid-Nottinghamshire ICP breakthrough objectives signed off July 2020</li> <li>Nottingham and Nottinghamshire Integrated Care System Board</li> <li>Continued engagement with ICP and ICS planning and governance arrangements</li> <li>Quarterly ICS performance review with NHSI</li> <li>Joint development of plans at ICS level</li> <li>Finance Directors Group</li> <li>ICS Planning Group</li> <li>Alignment of Trust, ICS and ICP plans</li> <li>Trust CFO role as ICS Finance Director</li> <li>Independent chair for ICP</li> </ul>	<p>Continued misalignment in organisational priorities</p> <p>Exec to Exec meetings with mid-Nottinghamshire CCG and Nottinghamshire Healthcare have been paused – attempting to re-start</p>	<p>ICS governance review to include:</p> <ul style="list-style-type: none"> <li>Roles and responsibilities of the ICS Board</li> <li>Governance manual</li> <li>New ICS Chair <del>to be appointed and starts in Feb 2021</del> started in February 2021</li> </ul> <p><b>SLT Lead:</b> Chief Executive Officer <b>Timescale:</b> under review <del>December 2020</del> June 2021</p> <p>Restore Exec to Exec meetings with mid-Nottinghamshire CCG and Nottinghamshire Healthcare <b>SLT Lead:</b> Chief Executive Officer <b>Timescale:</b> Will review <del>once we move out of wave two at an appropriate time</del> CEO meetings and other exec to exec meetings continue Board to Board with Notts Healthcare agreed for early April 2021. CEO and Chair of NUH, NHC and SFH met in February.</p>	<p><b>Management:</b> Alliance Development Summary to Board; Strategic Partnerships Update to Board; mid-Nottinghamshire ICP delivery report to FC (as meeting schedule); Finance Committee report to Board; Nottingham and Nottinghamshire ICS Leadership Board Summary Briefing to Board; Planning Update to Board <b>Risk &amp; compliance:</b> Significant Risk Report to RC monthly <b>Independent assurance:</b> 360 Assurance review of SFH readiness to play a full part in the ICS – Significant Assurance</p>	<p>Delay in delivering the benefits of system working due to the impact of COVID-19</p>	Inconclusive
<p><b>Threat and Opportunity:</b> Clinical service strategies and/or commissioning intentions that do not sufficiently anticipate evolving healthcare needs of the local population and/or reduce health inequalities</p>	<ul style="list-style-type: none"> <li>Continued engagement with commissioners and ICS developments in clinical service strategies focused on prevention</li> <li>Partnership working at a more local level, including active participation in the mid-Nottinghamshire ICP</li> <li>Clinical Services Strategy - 5 of 20 services complete</li> </ul>	<p>Insufficient granularity of plans to meet the needs of the population and the statutory obligations of each individual organisation</p>	<p>Development of a co-produced clinical services strategy for the ICS footprint – 2<sup>nd</sup> set of 5 services <b>SLT Lead:</b> Medical Director 5 of 20 services complete as at October 2019 <b>Timescale:</b> end <del>December 2020</del> June 2021</p>	<p><b>Management:</b> Alliance Development Summary to Board; Strategic Partnerships Update to Board; mid-Nottinghamshire ICP delivery report to FC (as meeting schedule); Finance Committee report to Board; Planning Update to Board <b>Independent assurance:</b> none currently in place</p>	<p>Delay in delivering the benefits of system working due to the impact of COVID-19</p>	Inconclusive

Formatted: Indent: Left: 0.3 cm, Hanging: 0.25 cm

## Board Assurance Framework (BAF): April 2021

<b>Principal risk</b> <small>(what could prevent us achieving this strategic priority)</small>	<b>PR 7: Major disruptive incident</b> A major incident resulting in temporary hospital closure or a prolonged disruption to the continuity of core services across the Trust, which also impacts significantly on the local health service community						<b>Strategic priority</b>	1: To provide outstanding care
<b>Lead Committee</b>	Risk	<b>Risk rating</b>	<b>Current exposure</b>	<b>Tolerable</b>	<b>Target</b>	<b>Risk type</b>	Services	
<b>Executive lead</b>	Director of Corporate Affairs	<b>Consequence</b>	<b>4. High</b>	4. High	4. High	<b>Risk appetite</b>	Cautious	
<b>Initial date of assessment</b>	01/04/2018	<b>Likelihood</b>	<del>3. Possible</del> <b>2. Unlikely</b>	3. Possible	1. Very unlikely			
<b>Last reviewed</b>	13/04/2021	<b>Risk rating</b>	<del>12. High</del> <b>8. Medium</b>	<b>12. High</b>	<b>4. Low</b>			
<b>Last changed</b>	13/04/2021							



Formatted Table

<b>Strategic threat</b> <small>(what might cause this to happen)</small>	<b>Primary risk controls</b> <small>(what controls/ systems &amp; processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)</small>	<b>Gaps in control</b> <small>(are further controls possible in order to reduce risk exposure within tolerable range?)</small>	<b>Plans to improve control</b> <small>(are further controls possible in order to reduce risk exposure within tolerable range?)</small>	<b>Sources of assurance (and date)</b> <small>(Evidence that the controls/ systems which we are placing reliance on are effective)</small>	<b>Gaps in assurance / actions to address gaps and issues relating to COVID-19</b>	<b>Assurance rating</b>
<b>Threat:</b> A large-scale cyber-attack that shuts down of the IT network due to a large-scale cyber-attack or system failure that and severely limits the availability of essential information for a prolonged period	<ul style="list-style-type: none"> <li>Information Governance Assurance Framework (IGAF) &amp; NHS Cyber Security Strategy</li> <li>Cyber Security Programme Board &amp; Cyber Security Project Group and work plan</li> <li>Cyber news – circulated to all NHS partners</li> <li>Network accounts checked after 50 days of inactivity – disabled after 80 days if not used</li> <li>Major incident plan in place</li> <li>Periodic phishing exercises carried out by 360 Assurance</li> <li>Spam and malware email notifications circulated</li> </ul>			<p><b>Management:</b> Data Protection and Security Toolkit submission to Board Mar '20 - 100% compliance; Hygiene Report to Cyber Security Board monthly; NHS report to Risk Committee quarterly; IG Bi-annual report to Risk Committee; Cyber Security and COVID-19 Report to Board May '20</p> <p><b>Independent assurance:</b> 360 Assurance Cyber Security Governance Report Jan '19 – Significant Assurance; 360 Assurance Data Security and Protection Toolkit Independent Assessment Mar '20 – High confidence in submission; ISO 27001 Information Security Management Certification; TIAN / 360 Assurance Cyber Security Survey - The impact of Covid-19 on the NHS Dec '20; <a href="#">CCG Cyber Security Report Mar '21- Significant Assurance</a></p>	<p>Insufficient assurance regarding governance and interface with NHS</p> <p>360 Assurance internal audit of governance and interface – <del>ToRs agreed</del> <a href="#">final report in draft</a></p> <p><b>SLT Lead:</b> Medical Director <b>Timescale:</b> <del>January-February</del> 2021</p>	Positive
<b>Threat:</b> A critical infrastructure failure caused by an interruption to the supply of one or more utilities (electricity, gas, water), an uncontrolled fire or security incident or failure of the built environment that renders a significant proportion of the estate inaccessible or unserviceable, disrupting services for a prolonged period	<ul style="list-style-type: none"> <li>Premises Assurance Model Action Plan</li> <li>Estates Strategy 2015-2025</li> <li>PFI Contract and Estates Governance arrangements with PFI Partners</li> <li>Fire Safety Strategy</li> <li>NHS Supply Chain resilience planning</li> <li>Emergency Preparedness, Resilience &amp; Response (EPRR) arrangements at regional, Trust, division and service levels</li> <li>Operational strategies &amp; plans for specific types of major incident (e.g. industrial action; fuel shortage; pandemic disease; power failure; severe winter weather; evacuation; CBRNe)</li> <li>Gold, Silver, Bronze command structure for major incidents</li> <li>Business Continuity, Emergency Planning &amp; security policies</li> <li>Resilience Assurance Committee (RAC) oversight of EPRR</li> <li>Independent Authorising Engineer (Water)</li> <li>Major incident plan in place</li> </ul>	Operational resilience of the Central Sterile Services Department (CSSD)	<p>Surgery division to present the preferred CSSD service provision option to the Executive team</p> <p><b>SLT Lead:</b> Divisional General Manager - Surgery <b>Timescale:</b> end <del>January</del> <a href="#">February 2021 – complete</a></p> <p><a href="#">Surgery division to present the CSSD service business case to the Executive team</a> <b>SLT Lead:</b> Divisional General Manager - Surgery <b>Timescale:</b> <a href="#">May 2021</a></p>	<p><b>Management:</b> Central Nottinghamshire Hospitals plc monthly performance report; Fire Safety Annual Report; <a href="#">Condition of retained estate (CCU Water System) update to Risk Committee Jan '19</a> <a href="#">Water Safety Update Report to Risk Committee Jul '20</a></p> <p><b>Risk &amp; compliance:</b> Monthly Significant Risk Report to Risk Committee</p> <p><b>Independent assurance:</b> Premises Assurance Model to RC Dec '18; EPRR Report; EPRR Core standards compliance rating (Oct '19) – Substantial Assurance; Water Safety report (WSP) to Joint Liaison Committee Oct '19; WSP report – hard FM independent audit; <a href="#">MEMD ISO 9001:2015 Recertification Mar '21</a></p>	<p>Insufficient assurance of hard and soft FM contractor performance</p> <p>Monitor hard and soft FM performance and provide periodic assurance reports</p> <p><b>SLT Lead:</b> Associate Director of Estates &amp; Facilities <b>Timescale:</b> up to end March 2021</p>	Positive

Formatted: Font: 10 pt

Formatted Table

## Board Assurance Framework (BAF): April 2021

Strategic threat <small>(what might cause this to happen)</small>	Primary risk controls <small>(what controls/ systems &amp; processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)</small>	Gaps in control <small>(are further controls possible in order to reduce risk exposure within tolerable range?)</small>	Plans to improve control <small>(are further controls possible in order to reduce risk exposure within tolerable range?)</small>	Sources of assurance (and date) <small>(Evidence that the controls/ systems which we are placing reliance on are effective)</small>	Gaps in assurance / actions to address gaps and issues relating to COVID-19	Assurance rating
<b>Threat:</b> A critical supply chain failure that severely restricts the availability of essential goods, medicines or services for a prolonged period	<ul style="list-style-type: none"> <li>▪ NHS Supply Chain resilience planning Business Continuity Management System &amp; Core standards</li> <li>▪ CAS alert system – Disruption in supply alerts</li> <li>▪ Major incident plan in place</li> <li>▪ PPE Strategy</li> <li>▪ PPE Winter Forecast 2020/21</li> <li>▪ EU Exit Preparation Meetings</li> <li>▪ COVID-19 Pandemic Surge Plan</li> <li>▪ Procurement Influenza Pandemic Business Continuity Plan</li> <li>▪ Interim provision for transmission of personal data to the United Kingdom clause within the EU Exit agreement</li> </ul>	None	N/A	<b>Management:</b> Procurement Annual Report to Audit & Assurance Committee; Oxygen Supply Assurance report to Incident Control Team Apr '20; COVID-19 Governance Assurance Report to Board May '20 <b>Independent assurance:</b> Internal Audit Business Continuity and Emergency Planning Sep '18 – Significant Assurance; 2019/20 Counter Fraud, Bribery and Corruption Annual Report; EU Exit Risk System Overview – Nottingham and Nottinghamshire System Dec '20	<b>Security of supplies due to:</b> <del>– Unknown impact of Brexit on critical items including medicines</del> <del>- Potential ban on exports to the UK from China</del>	Positive

Formatted: Font: (Default) Calibri, 10 pt, Font color: Black